Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Related Keywords

Alexey Danilov ,Kami Maddocks , ,Optimizing Bruton Kinase ,Mantle Cell Lymphoma ,Kinase Inhibitors ,Refractory Mantle Cell ,